|
|
|
|
| LEADER |
01827 am a22002053u 4500 |
| 001 |
112264 |
| 042 |
|
|
|a dc
|
| 100 |
1 |
0 |
|a Kaiser, Tobias
|e author
|
| 100 |
1 |
0 |
|a Massachusetts Institute of Technology. Department of Brain and Cognitive Sciences
|e contributor
|
| 100 |
1 |
0 |
|a McGovern Institute for Brain Research at MIT
|e contributor
|
| 100 |
1 |
0 |
|a Kaiser, Tobias
|e contributor
|
| 100 |
1 |
0 |
|a Feng, Guoping
|e contributor
|
| 700 |
1 |
0 |
|a Feng, Guoping
|e author
|
| 245 |
0 |
0 |
|a Modeling psychiatric disorders for developing effective treatments
|
| 260 |
|
|
|b Nature Publishing Group,
|c 2017-11-21T20:19:44Z.
|
| 856 |
|
|
|z Get fulltext
|u http://hdl.handle.net/1721.1/112264
|
| 520 |
|
|
|a Recent advances in identifying risk-associated genes have provided unprecedented opportunities for developing animal models for psychiatric disease research with the goal of attaining translational utility to ultimately develop novel treatments. However, at this early stage, successful translation has yet to be achieved. Here we review recent advances in modeling psychiatric disease, discuss the utility and limitations of animal models, and emphasize the importance of shifting from behavioral analysis to identifying neurophysiological abnormalities, which are likely to be more conserved across species and thus may increase translatability. Looking forward, we envision that preclinical research will align with clinical research to build a common framework of comparable neurobiological abnormalities and to help form subgroups of patients on the basis of similar pathophysiology. Experimental neuroscience can then use animal models to discover mechanisms underlying distinct abnormalities and develop strategies for effective treatments.
|
| 520 |
|
|
|a National Institute of Mental Health (U.S.) (Grant 5R01MH097104)
|
| 655 |
7 |
|
|a Article
|
| 773 |
|
|
|t Nature Medicine
|
